Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737076 | 1.00 | CES2 (0.43) | CES2CES1AKR1B1CTSLHDAC3 | |
| SCHEMBL1173626 | 0.82 | HDAC1 (0.41) | CES2CES1HDAC3HDAC1HDAC2 | |
| SCHEMBL6130072 | 0.80 | CES2 (0.44) | CES2CES1AKR1B1HDAC3HDAC1 | |
| SCHEMBL7737201 | 0.79 | CES2 (0.40) | CES2CES1AKR1B1CTSLHDAC3 | |
| SCHEMBL7737204 | 0.79 | CES2 (0.40) | CES2CES1AKR1B1CTSLHDAC3 | |
| SCHEMBL29028265 | 0.78 | CES2 (0.43) | CES2CES1AKR1B1HDAC3HDAC1 | |
| SCHEMBL2146350 | 0.78 | CES2 (0.43) | CES2CES1AKR1B1CTSLHDAC3 | |
| SCHEMBL3851045 | 0.77 | CYP3A4 (0.53) | CES2CES1AKR1B1CYP3A4CYP2C9 | |
| SCHEMBL19936196 | 0.76 | CES2 (0.38) | CES2CES1AKR1B1CTSLMEN1 | |
| SCHEMBL6159698 | 0.76 | ATM (0.45) | CES2CES1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337536-B1 | CATIONIC GROUP-3 CATALYST SYSTEM | EXXONMOBIL CHEM PATENTS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7390861-B2 | Cationic group-3 catalyst system | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20040033891-A1 | Cationic group-3 catalyst system | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-02-19 | — | — | US | disclosed |
| US-6407096-B1 | 1,4-BENZOTHIAZINE AND 1,4-BENZOXAZINE DERIVATIVES; HYPOTENSIVE, ANTIISCHEMIC, ANTIALLERGEN, ANTIASTHMATIC AND ANTICOAGULANT AGENTS; CARDIOVASCULAR DISORDERS | TORAY INDUSTRIES, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-1028113-A1 | FUSED BENZENE HETEROCYCLE DERIVATIVES AND UTILIZATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
| US-4105685-A | B-HALOGENO-ETHYL SILANES | CIBA-GEIGY CORPORATION (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033891-A1 | Cationic group-3 catalyst system | COG3, ORC3, LIG3 | CES2 2869/4885CES1 4534/4885AKR1B1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.